Darunavir Krka 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification
Decision 
Information 
1 issued on 
Issued2 / 
affected3  
amended 
on 
IB/0015 
C.I.2.a - Change in the SPC, Labelling or PL of a 
12/05/2023 
SmPC and PL 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
IB/0014 
C.I.2.a - Change in the SPC, Labelling or PL of a 
09/02/2023 
SmPC and PL 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
R/0013 
Renewal of the marketing authorisation. 
15/09/2022 
09/11/2022 
SmPC and PL 
Based on the review of data on quality, safety and efficacy, 
the CHMP considered that the benefit-risk balance of 
Darunavir Krka in the approved indication remains 
favourable and therefore recommended the renewal of the 
marketing authorisation with unlimited validity. 
IB/0012/G 
This was an application for a group of variations. 
16/06/2022 
n/a 
B.I.c.z - Container closure system of the AS - Other 
variation 
B.I.b.1.b - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Tightening of 
specification limits 
B.I.a.3.a - Change in batch size (including batch size 
ranges) of AS or intermediate - Up to 10-fold 
increase compared to the originally approved batch 
size 
A.7 - Administrative change - Deletion of 
manufacturing sites 
B.I.a.2.e - Changes in the manufacturing process of 
the AS - Minor change to the restricted part of an 
ASMF 
B.I.b.2.e - Change in test procedure for AS or 
Page 2/6 
 
 
 
 
 
 
 
 
 
 
 
 
 
starting material/reagent/intermediate - Other 
changes to a test procedure (including replacement 
or addition) for the AS or a starting 
material/intermediate 
B.I.b.2.e - Change in test procedure for AS or 
starting material/reagent/intermediate - Other 
changes to a test procedure (including replacement 
or addition) for the AS or a starting 
material/intermediate 
B.I.c.2.c - Change in the specification parameters 
and/or limits of the immediate packaging of the AS - 
Deletion of a non-significant specification parameter 
(e.g. deletion of an obsolete parameter) 
B.I.c.3.b - Change in test procedure for the 
immediate packaging of the AS - Other changes to a 
test procedure (including replacement or addition) 
B.I.c.2.a - Change in the specification parameters 
and/or limits of the immediate packaging of the AS - 
Tightening of specification limits 
B.I.c.2.a - Change in the specification parameters 
and/or limits of the immediate packaging of the AS - 
Tightening of specification limits 
B.I.d.1.a.4 - Stability of AS - Change in the re-test 
period/storage period - Extension or introduction of a 
re-test period/storage period supported by real time 
data 
IB/0011 
C.I.2.a - Change in the SPC, Labelling or PL of a 
16/12/2021 
09/11/2022 
SmPC and PL 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
Page 3/6 
 
 
 
 
 
 
 
new additional data is required to be submitted by 
the MAH 
IB/0010 
C.I.2.a - Change in the SPC, Labelling or PL of a 
05/10/2021 
09/11/2022 
SmPC and PL 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IA/0009 
B.II.e.1.a.1 - Change in immediate packaging of the 
14/04/2021 
n/a 
finished product - Qualitative and quantitative 
composition - Solid pharmaceutical forms 
IB/0008 
C.I.2.a - Change in the SPC, Labelling or PL of a 
20/11/2020 
17/12/2020 
SmPC and PL 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IB/0007 
B.II.f.1.b.1 - Stability of FP - Extension of the shelf 
08/07/2020 
17/12/2020 
SmPC 
life of the finished product - As packaged for sale 
(supported by real time data) 
IB/0006/G 
This was an application for a group of variations. 
05/12/2019 
18/12/2019 
SmPC, Annex 
II and PL 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
Page 4/6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
new additional data is required to be submitted by 
the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IA/0005 
A.5.b - Administrative change - Change in the name 
25/06/2019 
n/a 
and/or address of a manufacturer/importer of the 
finished product, including quality control sites 
(excluding manufacturer for batch release) 
IB/0004 
B.II.f.1.b.2 - Stability of FP - Extension of the shelf 
27/03/2019 
18/12/2019 
SmPC, 
life of the finished product - After first opening 
(supported by real time data) 
Labelling and 
PL 
IA/0003 
B.II.b.4.b - Change in the batch size (including batch 
21/01/2019 
n/a 
size ranges) of the finished product - Downscaling 
down to 10-fold 
IB/0002/G 
This was an application for a group of variations. 
08/11/2018 
10/12/2018 
SmPC and PL 
C.I.2.a - Change in the SPC, Labelling or PL of a 
Page 5/6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
C.I.z - Changes (Safety/Efficacy) of Human and 
Veterinary Medicinal Products - Other variation 
IB/0001/G 
This was an application for a group of variations. 
13/06/2018 
10/12/2018 
SmPC and PL 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
Page 6/6 
 
 
 
 
 
 
 
 
 
 
